Category Archives: Biotechnology

DanielPrudek/iStock via Getty Images

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) is a healthcare exchange traded fund (ETF) launched by BlackRock, Inc. in June 2019, i.e., less than three years back. This ETF is managed by BlackRock Fund Advisors and has an Asset Under Management (AUM) of $209 million. It invests in public equity shares in all the major stock markets worldwide, with 60 percent investments in the US stock market. This ETF has around 11 percent investments in the Japanese stock market and 24 percent investments in European equity markets.

iShares Genomics Immunology and Healthcare ETF primarily invests in biotechnology and pharmaceutical stocks. It has also invested around 3 percent in a dividend fund, namely Eaton Vance Tax-Advantaged Dividend Income Fund (EVT). IDNA benchmarks the performance of its portfolio against the NYSE FactSet Global Genomics and Immuno Biopharma Index. This index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

iShares Genomics Immunology and Healthcare ETF is a relatively new ETF, launched less than three years ago, and is operating with an expense ratio of 0.47 percent. This ETF is not meant for income-seeking investors, as it intends to pay semi-annual dividends, but with a very low yield. The average year-end yield of the past three years has been less than 0.6 percent. Thus, the investment decision will solely depend upon the expected future performance of the fund over the long run.

iShares Genomics Immunology and Healthcare ETF has performed poorly over the past 12 months. IDNA has recorded a negative growth of around 9 percent, 40 percent, and 38 percent over the past three months, six months, and 12 months, respectively. We all know that the biotechnology sector had an extremely poor last six months in 2021. Still, for a growth-seeking ETF to generate a negative return of that high percentage may make the investors skeptical.

An analysis of IDNA's top 30 common equity holdings (holding 90 percent of the entire portfolio) reveals that most of its investments are in biotechnology stocks. Out of these 30 equities, 24 biotechnology stocks (22 are listed in the US stock market) are holding more than 60 percent of its total portfolio.

Only five stocks are from the pharmaceutical sector, holding around 26 percent of its total portfolio. Incidentally, all these five stocks are listed outside the United States. One of IDNA's top holdings (3.85 percent of total portfolio), Maravai LifeSciences Holdings, Inc. (MRVI), belongs to the life sciences tools & services industry.

Barring Regeneron Pharmaceuticals, Inc. (REGN), all the biotechnology and life science companies listed in the New York Stock Exchange (NYSE) have recorded negative price growth over the past 12 months. This explains the massive loss of IDNA's price over the past one year. Another company, Exelixis, Inc. (EXEL) recorded positive price growth over the past six months.

Another three stocks - Maravai LifeSciences Holdings, Inc., Iovance Biotherapeutics, Inc. (IOVA), and Genmab A/S (GMAB) - recorded double-digit positive growth in the past three months. Thus, this ETF seems to be slowly recovering from the steep downfall in the second half of 2021. Still, it has a long way to go, as 20 such companies are yet to recover themselves.

iShares Genomics Immunology and Healthcare ETF, however, has posted a price growth of 22 percent since its inception in June 2019. This suggests that this ETF has performed very well in the first two years of its operation, and the stocks included in this ETF are quite volatile. There are other genomic revolution funds like Invesco Dynamic Biotechnology & Genome Portfolio ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM) and ARK Genomic Revolution ETF (ARKG), which also performed poorly last year. The similar trend is visible in most of the funds - huge price loss in the past 12 months, but positive price gain since June 2019 (the time when IDNA was launched).

Despite the market price falling by 61.1 percent in the past one year, ARKG registered a growth of 3.3 percent over the past three years. PBE's price also fell by 25.3 percent in the past one year but grew by 7.8 percent over the past three years. Only GNOM failed miserably and recorded a negative growth of 44.5 percent and 13.9 percent growth over the past one year and three years, respectively. During the same period, S&P 500 OTC:GREW by 4 percent and 53 percent, respectively.

Weighted average Price to Equity ratio of the component stocks of iShares Genomics Immunology and Healthcare ETF comes to around 14.29, compared to the index's Price to Equity ratio of 16.67. IDNA's Price to Book ratio is 2.23, compared to the index's Price to Book ratio of 3.98. This suggests that the ETF is slightly undervalued. This assumption gets further validation as the price/sales of 1.27, and price/cash flow of 9.7, is relatively lower than the index (Price/Sales of 1.64 and Price/Cash Flow of 13.35).

However, the iShares Genomics Immunology and Healthcare ETF is currently trading at only 3 percent premium over its 52-week low, and there is scope for a further downward rally of this fund, as indicated by the simple moving averages (SMA). The long-term moving averages of this fund are placed significantly higher than the short-term moving averages. As of 28th April 2022, the 200-day SMA (43.67), 100-day SMA (36.73), 50-day SMA (33.54) and 10-day SMA (31.82) are indicative of a bearish rally for this ETF.

Thus, there lies every possibility of stiff downward movement with every downward trend in the market. Moreover, being a theme-based biotechnology index fund, IDNA cannot overcome its inherent volatility and market risk, which may arise due to changes in investors' sentiment or any negative news about its constituent stocks or the sector as a whole. The possibility of most of the stocks in its portfolio generating positive returns will take time, maybe another six to nine months. However, a course correction for IDNA is very much possible, too, if the biotechnology sector gets some positive boost or gets into any bull run.

In my opinion, iShares Genomics Immunology and Healthcare ETF can only be considered as a medium or long-term investment option. Genomic revolution has good growth prospects, which may enable these biotechnology stocks to generate supernormal growth. Moreover, a few of the biotechnology stocks that IDNA holds have started generating positive returns. Besides, the pharmaceutical stocks listed in other equity markets have always maintained a good return.

The overall price growth since the inception of this fund is quite impressive, considering the huge impact of Covid-19 pandemic in the US equity market. Although the portfolio of investments is expected to generate positive return in the medium term, iShares Genomics Immunology and Healthcare ETF is a better prospect for long-term growth-seeking investors. However, it is advisable that such long-term growth seekers hedge themselves with put options, in order to protect their investments from likely downward movements, which may happen from time to time.

Visit link:
IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally - Seeking Alpha

The MS in Biotechnology program offers track options inBioBusiness,BioScience,Drug Design and Discovery,Entrepreneurship, andIndustrial Sciencesas well as flexibility for anIndividualized Track. We focus on developing leadership skills, teamwork and entrepreneurship that are essential for career success.

A highlight of the program is thecapstone internship, which allows students to gain the desired work experience. Internship opportunities are available in all the tracks that include research in industry, academic, and government laboratories and in business development, marketing, commercialization, finance, regulatory affairs, and technology transfer.

Georgetown Biotech Students & Alumni LinkedIn

If this is your first time hearing about the Georgetown Biotechnology Program, our Information Sessions are a great start for you! The goal of the Information Sessions is to give interested students an overview of the Georgetown Biotechnology Program and to engage in an interactive dialogue with our prospective students who are discovering the next generation of biotechnology. We will be hosting the following webinar(s):

We look forward to meeting you virtually and to hearing your questions about the M.S. in Biotechnology. Please RSVP above.

If you have heard about the Georgetown Biotechnology Program and have been engaged with us during the admission process, Come n Mingle with faculty, alumni, and current students to learn more about our program. We will be hosting the following webinar(s):

If you have a passion for science, health, and biotechnology and would like to explore these subjects in-depth before college, here is your chance to do so with the High School Biotechnology for Science & Health Academy this summer! For more information, visit our website.

The Georgetown Biotechnology Program is thrilled to introduce two new topics to its curriculum: new courses in Vaccine Development and Gene Therapy will cover the most current knowledge and business aspects of their fields. Courses like these will allow our students to become versed in the most cutting-edge technologies and build their skills and expertise towards 21st century needs. Students will learn the scientific, business, and regulatory modalities of vaccine development and gene therapy through these new additions to our program.

Georgetown University will require students, faculty and staff who return to campus this fall to be vaccinated against the coronavirus.

Read more:
Masters in Biotechnology Program | Georgetown University

Request Information

Biotechnology is a swiftly growing industry. From the food grown at our farms to the medicine we buy and the ways we clean up the environment, biotechnology affects many facets of our daily lives. Major developments in the field occur every day, with many introduced by academic and professional communities before the greater public is even aware of industry advancements.

At the School of Engineering, youll join in these exciting discoveries. Course topics range from industrial application of enzymes and bio-polymer synthesis to modern drug design and the role of biotechnology in health care. The availability of various and varied electives enables you to specialize in selected biotechnology areas.

The program also includes Advanced Cell and Molecular Biology and Genetic Engineering courses, both with labs. Students can further enhance their research and analytical skills by registering for a Guided Study course. Taking two such courses will enable students to complete a body of research work equivalent to a master's thesis (optional). Students can also take a business- or management-related course from Biotechnology and Entrepreneurship M.S.

Other electives are available for both programs. For further details please visitBiotechnolgy, M.S. curriculum belowand theBiotechnology and Entrepreneurship, M.S. curriculum.

With advisors permission students can take courses at other Schools of NYU.

There are ample research/internship opportunities available at NYU and NYC at large. For example, many Biotech M.S. students participate in research projects at the NYU Langone Medical Center, the world-renowned Memorial Sloan Kettering Cancer Center, and other research institutions in the city. There are also internships in Biotech start-ups. All students can, of course, apply for summer internships at big pharmaceutical companies. To learn more about these opportunities see what our students say below.

Find outabout AdmissionRequirements.

What Our Students Say

See the rest here:
Biotechnology, M.S. | NYU Tandon School of Engineering

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.

The companys management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the Investors section of the company website at: http://www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit http://www.nautilus.bio.

Contacts

Investors:InvestorRelations@nautilus.bio

Media:Thermal for Nautilus BiotechnologyKaustuva DasPress@nautilus.bio

Original post:
Nautilus Biotechnology to Announce First Quarter 2022 ...

If you're thinking about breaking into the biotechnology industry, you might be feeling overwhelmed by all the jobs that are encompassed within that sector. Where do you start your job search? How do you know if you'll be qualified for the biotech position you want? Luckily, we have done the research for you and put together a guide to help you decide where to go within the biotech field.

We will cover the wide range of jobs you could have while working in the biotech industry. We'll also discuss what type of background is best for switching to the industry and what level of education you should complete before applying to most positions.

Keep in mind that there are always exceptions you might be surprised by the ways that skills from other careers might transfer over and still be useful within the biotechnology industry.

What Are Biotechnology Jobs?

Biotechnology is a branch of biology that involves utilizing natural, biological processes for the purpose of benefiting mankind. In other words, it's the use of various techniques, like genetic manipulation and DNA sequencing, to understand more about biology and create a product that can be used to help others.

There are many different types of jobs that fall under the biotech umbrella. Biotechnology, as a practice, works its way into many fields of science as it relates to animals, humans, food safety and more. Biotechnology understanding can be applied to health and medical sciences, biomedical engineering, agriculture, immunology, virology and more.

Most biotechnology positions involve working in research or product development labs. Depending on your area of expertise, you could research living organisms and use technology to chart and expand upon your findings. In general, that research is used to create products that can help others within the field, whether it's discovering new medicine, creating standards for chemistry, understanding water quality goals, advancing biology understandings or contributing to ongoing research.

Aside from research, there are also several technician roles and technical support positions available within multiple fields that utilize biotechnology understanding. If you're unsure about where to begin in your biotech job search, it's best to search using an industry-specific job board.

Some examples of job areas in biotech include:

Though you can secure these jobs with a biotechnology degree from an accredited university, that is not the only path you can take. You can just as easily transfer to the biotechnology field from different careers. With education, understanding and practice, you can work in practically any field you want, regardless of your background.

What Qualifications Do I Need To Work In Biotechnology?

As stated above, most biotechnology jobs rely heavily on research and analysis. No matter what your background is, you'll need to have demonstrable research and analysis skills that you can lean on for a job in biotech.

With research skills also comes an understanding of the industry and an understanding of the topics being researched. Critical thinking, observation and technical skills are also very important for anyone working in biotech. Also, experience working in a laboratory in any capacity will hold some weight when applying for biotech positions since you'd likely be working in a lab in that career.

On top of those skills, many biotech recruitersexpect their applicants to have a Bachelor's degree in biotechnology or a related field, like biology, chemistry or natural sciences. Some positions, like those in the agricultural and food science fields, may accept an Associate's Degree instead. Some will also consider applicants who have certificates in biotechnology.

Professionals who work in advanced scientist positions will often have a Master's or Ph.D in the topic of the field they are covering. People who have worked in the field at length will commonly move to a manager or postsecondary teaching position later in their career.

Which Industries Are Best For A Career Change To Biotechnology?

Changing careers from a different field to biotechnology may seem daunting, but it is definitely possible.

The best careers to work in before switching to biotechnology are any that are already within a scientific field. Being able to prove and show examples of your understanding of working within a scientific lab or research facility will make you a more marketable candidate for biotechnology positions.

Careers with a heavy technology background, like computer system analysts, programmers and developers, might also have a good chance of switching to biotech because they have already mastered an understanding of data collection and analysis.

Working in healthcare in any capacity requires an understanding of biology and the way it relates to our everyday lives. This type of understanding will look good to biotech recruiters because biology is at the heart of all biotech positions. Similarly, careers in math or physics transfer well to biotech positions.

Professionals working in communication roles may also have a potential job within the biotech industry because there is always a need for written reports of study findings and explanations of that analysis. With the way biotech is expanding, communicating findings to the general public is more important than ever, especially considering that all parts of biotechnology have the goal of enhancing a community's lives in one way or another.

The Bureau of Labor Statistics published data that shows biotechnology is a growing field with some of the most competitive wages and compensation in the country. Our society is becoming more and more reliant on biological advancements and there will always be a need in the field for more researchers and experts.

In Conclusion

Switching from your career path to something entirely different like biotechnology may seem impossible, but it's not. Individuals with the right set of skills and a relatable background will be able to find a position in the biotech field if they are consistent in searching for it.

No matter what your background is or how old you are, you can learn new skills and take individual classes to learn more about research, analysis and how biotechnology relates to your life or the subject you hope to study. There are countless jobs, many of which people don't know about, within biotechnology that are open or will be open in the near future as the field continues to expand.

Link:
Is a Career in Biotech Right for You? - BioSpace

Equities research analysts expect Puma Biotechnology, Inc. (NASDAQ:PBYI Get Rating) to report earnings per share (EPS) of ($0.13) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Puma Biotechnologys earnings. Puma Biotechnology posted earnings of $0.40 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 132.5%. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Puma Biotechnology will report full year earnings of $0.16 per share for the current financial year, with EPS estimates ranging from $0.06 to $0.25. For the next financial year, analysts anticipate that the company will report earnings of $0.63 per share, with EPS estimates ranging from $0.35 to $0.91. Zacks Investment Researchs EPS averages are a mean average based on a survey of research firms that follow Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYI Get Rating) last issued its quarterly earnings results on Thursday, March 3rd. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.11) by $0.21. Puma Biotechnology had a negative net margin of 11.49% and a negative return on equity of 357.74%. The company had revenue of $55.40 million during the quarter, compared to analysts expectations of $47.17 million. During the same quarter last year, the company posted ($0.38) EPS. The firms revenue was up 5.3% compared to the same quarter last year.

Large investors have recently bought and sold shares of the stock. Invesco Ltd. grew its holdings in shares of Puma Biotechnology by 18.3% during the second quarter. Invesco Ltd. now owns 12,825 shares of the biopharmaceutical companys stock worth $118,000 after purchasing an additional 1,980 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Puma Biotechnology by 64.4% during the fourth quarter. BNP Paribas Arbitrage SA now owns 11,354 shares of the biopharmaceutical companys stock worth $35,000 after purchasing an additional 4,447 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Puma Biotechnology by 13.2% during the fourth quarter. Principal Financial Group Inc. now owns 50,445 shares of the biopharmaceutical companys stock worth $153,000 after purchasing an additional 5,883 shares during the last quarter. Diversified Trust Co grew its holdings in shares of Puma Biotechnology by 30.8% during the fourth quarter. Diversified Trust Co now owns 25,688 shares of the biopharmaceutical companys stock worth $78,000 after purchasing an additional 6,053 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Puma Biotechnology by 2.9% during the second quarter. Wells Fargo & Company MN now owns 224,470 shares of the biopharmaceutical companys stock worth $2,062,000 after buying an additional 6,314 shares during the period. 89.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ PBYI traded down $0.05 during mid-day trading on Friday, hitting $2.83. The company had a trading volume of 184,197 shares, compared to its average volume of 426,443. The company has a market capitalization of $116.96 million, a PE ratio of -3.93 and a beta of 1.02. Puma Biotechnology has a 1-year low of $2.06 and a 1-year high of $11.95. The businesss 50-day simple moving average is $2.68 and its 200 day simple moving average is $3.48.

About Puma Biotechnology (Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Puma Biotechnology, Inc. (NASDAQ:PBYI) Expected to Announce Earnings of -$0.13 Per Share - Defense World

Overview Of Biotechnology Reagents Market Insights 2022

The Biotechnology Reagents Market 2022 report provides a detailed analysis of the dynamic of the market with extensive focus on secondary research. The report sheds light on the current situation of the market size, share, demand, development patterns, and forecast in the coming years.

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The report Global Biotechnology Reagents Market analyzes the strategy patterns, and forecast in the coming years. The report evaluates the market size of the Global Biotechnology Reagents Market studies the strategy patterns adopted by the prominent international players.

Request a sample report @: https://globalmarketvision.com/sample_request/123016

Key Competitors of the Global Biotechnology Reagents Market are:

Life Technologies, (U.S.), Bio-Rad (U.S.), Thermo Fisher Scientific (U.S.), Water Corporation (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies Inc. (U.S.), Betcon Dickinson (U.S.), Beckman Coulter (U.S.), Roche (Switzerland), Abbott (U.S.).

Global Biotechnology Reagents Market Segmentation:

Market Segmentation: By Type

Life scienceAnalytical

Market Segmentation: By Application

Protein synthesis and purificationGene expressionDNA and RNA analysisDrug testing

The research report studies the past, present, and future performance of the global market. The report further analyzes the present competitive scenario, prevalent business models, and the likely advancements in offerings by significant players in the coming years.

The report includes company profiles of almost all major players in the Biotechnology Reagents market. The Company Profiles section provides valuable analysis of strengths and weaknesses, business trends, recent advances, mergers and acquisitions, expansion plans, global presence, market presence, and portfolios of products from major market players. This information can be used by players and other market participants to maximize their profitability and streamline their business strategies. Our competitive analysis also provides vital information that will help new entrants identify barriers to entry and gauge the level of competitiveness in the Biotechnology Reagents market.

Regional analysis of Biotechnology Reagents market covers:

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biotechnology Reagents Market in 2022.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Reasons for buying this Biotechnology Reagents Market report:

Table of Contents

Global Biotechnology Reagents Market Research Report 2022 2029

Chapter 1 Biotechnology Reagents Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Biotechnology Reagents Market Forecast

Buy Exclusive [emailprotected] https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=123016

If you have any special requirements, please let us know and we will offer you the report as you want.

About Global Market Vision

Global Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customers needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.

With our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.

Contact Us

Sarah Ivans | Business Development

Phone: +1-3105055739

Email: [emailprotected]

Global Market Vision

Website: http://www.globalmarketvision.com

Read more:
Biotechnology Reagents Market 2022 Detailed Analysis of top Ventures with Regional Outlook | Life Technologies, (US), Bio-Rad (US), Thermo Fisher...

The Research report provides an in-depth analysis of the impact of COVID-19 on numerous segments within the Rosmarinic Acid market-supported product types, applications, and key players like (Sabinsa, Shaanxi Yuantai Biological Technology, Natrusolate, ACE Biotechnology, Yongzhou Huamao Biotechnology, Naturalin Bio-Resources, and more) across various countries around the world. Further, the Rosmarinic Acid market report additionally provides insights into market developments, trends, provide and demand changes across numerous regions across the globe. The market is predicted to witness continuing growth throughout the forecast from 2022 to 2028. It commits various factors affecting industry like market environment, various policies of the government, past data and market trends, technological advancements, upcoming innovations, market risk factors, market restraints, and challenges within the industry. Then it analyzed the worlds main region market conditions, including the demand and supply chain analysis and industry rate of growth etc. At the top, the report introduced a new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request for Sample Copy of Rosmarinic Acid Market with Complete TOC and Figures & Graphs @ https://www.affluencemarketreports.com/industry-analysis/request-sample/2318611/

Whats Included in Sample Copy of Rosmarinic Acid Market Report:

Further, the report presents profiles of competitors in the Rosmarinic Acid market include:

The report provides an accurate analysis of the changing competitive dynamics. It provides a forward-looking perspective on the various factors that drive or restrict market growth. It provides a five-year forecast evaluated based on Rosmarinic Acid market growth projections. Helps in understanding the key product segments and their future, to gain a complete view of the market, and make informed business decisions by performing an in-depth analysis of the market segments.

Contact for Additional Customization in Rosmarinic Acid Market Report at https://www.affluencemarketreports.com/industry-analysis/request-inquiry/2318611/

Following Key Segments Covered in the Global Rosmarinic Acid Market Report:

Rosmarinic Acid Market Breakdown by Product Type:

Rosmarinic Acid Market Breakdown by Application:

Along with Rosmarinic Acid Market research analysis, buyer also gets valuable information about global Rosmarinic Acid Production and its market share, Revenue, Price and Gross Margin, Supply, Consumption, Export, import volume, and values for the following Regions:

Benefits of Rosmarinic Acid Market Report:

For More Details on the Impact of COVID-19 on Rosmarinic Acid Market, Connect with us at https://www.affluencemarketreports.com/industry-analysis/covid19-request/2318611/

For More Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number:

U.S: +1-(424) 256-1722

U.K.: +44 1158 88 1333

Email: [emailprotected]

Website: http://www.affluencemarketreports.com

Visit link:
Insights on Rosmarinic Acid Market: Facts, Figures and Trends 2022-2028 by Sabinsa, Shaanxi Yuantai Biological Technology, Natrusolate, ACE...

Evofem Biosciences, Inc. and Orion Biotechnology Canada Ltd. have entered into a collaboration agreement to evaluate the compatibility and stability of Orion's novel CCR5 antagonist, OB-002, in Evofem's Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.The collaboration will focus on determining compatibility and stability of OB-002 in Phexxi with results expected in 3Q22. Assuming positive results, the companies will seek government and philanthropic funding for subsequent clinical trials of the MPT vaginal gel product candidate."For too long, women have had to assemble a grab-bag of products to protect against pregnancy, various STIs, and HIV," said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences. "This partnership with Orion aims to develop a first-of-its-kind product with potential to revolutionize the way women protect their sexual and reproductive health: no unintended pregnancies, no STIs, and no HIV -- all in one applicator."Ian McGowan, Chief Medical Officer of Orion Biotechnology, added, "It is unacceptable that we are still seeing high rates of new HIV infections among women each year and there is clearly a compelling need to expand the HIV prevention portfolio. Orion is very excited to be collaborating with Evofem to address this important issue and develop an MPT product for women across the world."In trials to date of Orion's novel CCR5 antagonist, OB-002 has demonstrated best-in-class in vitro potency. OB-002 was 100% effective in blocking transmission of HIV infection in a non-human primate model. A 15-subject Phase 1 study of vaginally administered OB-002 gel demonstrated that the OB-002 gel was safe and well tolerated, with no evidence of systemic absorption.Phexxi is a hormone-free, on-demand prescription contraceptive vaginal gel that was launched in the U.S. in September 2020. Top-line data is expected from Evofem's pivotal Phase 3 trial for the prevention of chlamydia and gonorrhea in women in the second half of 2022.

View post:
http://www.contractpharma.com

Program Overview

Life sciences. Technology. Business.

Biotechnology is about making discoveries that make the world a better place, and about bringing those concepts to life and into the market. Spanning industries, including pharmaceuticals, agriculture, healthcare, environment, energy, national security, biotechnology covers roles from the R&D lab, product development, and manufacturing to sales, marketing, finance, and law.

This robust graduate program at Johns Hopkins University offers concentrations and elective courses that result in a degree designed to fit your career aspirations.

This rigorous, practical advanced degree prepares you for biotechnology-related roles in a range of industries and environments including:

The MS in Biotechnology also serves as a foundation for medical school or advanced studies in the life sciences or public health.

Designed for both part-time and full-time students, this biotechnology masters program offers you the flexibility to take classes online or on-campus in the evenings and on weekends.

View original post here:
MS in Biotechnology - Johns Hopkins Advanced Academic Programs